Immunome, Inc. (NASDAQ:IMNM) Receives $29.00 Consensus Price Target from Brokerages

Shares of Immunome, Inc. (NASDAQ:IMNM) have been given an average rating of “Buy” by the six analysts that are presently covering the company, MarketBeat reports. Six equities research analysts have rated the stock with a buy recommendation. The average 1-year price objective among brokerages that have issued ratings on the stock in the last year is $29.00.

IMNM has been the subject of several recent research reports. Wedbush reiterated an “outperform” rating and set a $33.00 price objective on shares of Immunome in a report on Friday, October 25th. Piper Sandler lowered their price target on Immunome from $27.00 to $23.00 and set an “overweight” rating on the stock in a research report on Tuesday, August 13th.

Immunome Stock Performance

Shares of NASDAQ IMNM opened at $12.54 on Friday. The stock has a fifty day moving average price of $13.43 and a two-hundred day moving average price of $13.90. The firm has a market cap of $753.08 million, a P/E ratio of -1.63 and a beta of 1.82. Immunome has a 1 year low of $6.93 and a 1 year high of $30.96.

Immunome (NASDAQ:IMNM) last released its earnings results on Monday, August 12th. The company reported ($0.49) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.11). The business had revenue of $2.36 million during the quarter, compared to analysts’ expectations of $2.62 million. Immunome had a negative net margin of 2,435.02% and a negative return on equity of 38.19%. On average, research analysts predict that Immunome will post -1.92 earnings per share for the current fiscal year.

Insider Transactions at Immunome

In other Immunome news, insider Jack Higgins sold 3,524 shares of the company’s stock in a transaction on Thursday, August 15th. The stock was sold at an average price of $13.93, for a total transaction of $49,089.32. Following the transaction, the insider now owns 16,000 shares of the company’s stock, valued at approximately $222,880. This represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other Immunome news, insider Jack Higgins sold 3,524 shares of the company’s stock in a transaction on Thursday, August 15th. The shares were sold at an average price of $13.93, for a total transaction of $49,089.32. Following the completion of the sale, the insider now owns 16,000 shares in the company, valued at approximately $222,880. The trade was a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Jean Jacques Bienaime bought 7,000 shares of the company’s stock in a transaction on Friday, August 16th. The shares were acquired at an average price of $13.94 per share, with a total value of $97,580.00. Following the transaction, the director now directly owns 16,615 shares in the company, valued at approximately $231,613.10. The trade was a 0.00 % increase in their position. The disclosure for this purchase can be found here. 8.60% of the stock is owned by company insiders.

Institutional Trading of Immunome

Large investors have recently made changes to their positions in the company. Quest Partners LLC bought a new stake in shares of Immunome in the 2nd quarter valued at $81,000. Zurcher Kantonalbank Zurich Cantonalbank bought a new stake in shares of Immunome in the 2nd quarter valued at $97,000. Arizona State Retirement System increased its position in shares of Immunome by 9.2% in the 2nd quarter. Arizona State Retirement System now owns 10,862 shares of the company’s stock valued at $131,000 after buying an additional 918 shares in the last quarter. EntryPoint Capital LLC boosted its stake in Immunome by 21,864.0% in the 1st quarter. EntryPoint Capital LLC now owns 5,491 shares of the company’s stock worth $136,000 after purchasing an additional 5,466 shares during the period. Finally, AQR Capital Management LLC boosted its stake in Immunome by 34.6% in the 2nd quarter. AQR Capital Management LLC now owns 16,064 shares of the company’s stock worth $194,000 after purchasing an additional 4,129 shares during the period. Institutional investors own 44.58% of the company’s stock.

Immunome Company Profile

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.